PJB-2024-354
Aroona Chabra
Abstract
Trichomonas vaginalis (T. vaginalis), a flagellate parasite, resides in the genital canal and is classified as a sexually transmitted disease. Scientists have administered many medications to treat this disease, with Metronidazole being considered the most effective option. However, the drug's multiple side effects have prompted them to hunt for a suitable alternative. The objective of the study was to assess the efficacy of nanoemodin derived from Rhamnus cathartica (R. cathartica) in eradicating T. vaginalis in a laboratory setting. The T. vaginalis samples were collected from the vaginal secretions of women referred to medical institutions in Mazandaran province, north Iran. We prepared ethanolic extracts of R. cathartica using nanoemodin at different concentrations. We performed a triplicate viability assay on trophozoites using different concentrations (50, 100, 200, 400, and 800 g/ml) of plant extract containing nanoemodin. We evaluated the viability of the trophozoites by utilizing trypan blue staining at 3, 6, 12, 24, and 48-hour time points with a Neubauer chamber. Both R. cathartica and nanoemodin extracts showed considerable antiparasitic action against the T. vaginalis parasite, regardless of their concentrations. Concentrations of 400 and 800 μg/ml of nanoemodin, in addition to 800 μg/ml of R. cathartica plant extract, demonstrated stronger anti-T. vaginalis effects compared to the positive control. The findings of the current study indicated that the inhibitory effects of R. cathartica particularly its extracted nanoemodin were higher than metronidazole. Further research is needed to confirm these findings in animal models and clinical trials, but the results so far are encouraging and warrant continued investigation into the therapeutic potential of nanoemodin for the treatment of trichomoniasis.
To Cite this article:
Download
